Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber
May 11, 2017
- Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
May 11, 2017
- Shionogi Wants to Zero In on Innovative Drugs, Teshirogi says on LLP Transfer
May 11, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
- Eisai Plans Japan Filing for Lenvima’s HCC Indication in June: CEO
May 11, 2017
- Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
May 11, 2017
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
- Fujifilm Invests 170 Million Yen in Regenerative Medicine Startup
May 11, 2017
- Takeda, UK Bioventure GammaDelta Pair Up for Development of New Immunotherapies Based on T cells
May 11, 2017
- Sales Rep Survey - 2: Drug Makers Exploring New Values amid Shift to Community-Based Care
May 10, 2017
- Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
- Takeda Calls off Hib Vaccine Launch on GSK’s Production Exit
May 10, 2017
- Japanese Drug Production Could Shrink to 6.8 Trillion Yen in 2024: Yano Research Institute
May 10, 2017
- BIKEN, Mitsubishi Tanabe Reach Final Agreement on Vaccine Joint Venture Slated to Begin Operation in September
May 10, 2017
- Daiichi Sankyo Starts Edoxaban Clinical Study in AF Patients following TAVI
May 10, 2017
- Eisai Suffers Setback in US Patent Litigation over Aloxi
May 9, 2017
- Mitsubishi Tanabe’s ALS Med Gets FDA Greenlight
May 9, 2017
- Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
- 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
- Brexpiprazole Delivers Mixed Results on AD Agitation: Otsuka, Lundbeck
May 8, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…